An investigation by The Herald has uncovered disturbing allegations of collusion and potential wrongdoing within the Food and Drugs Authority (FDA) regarding a colossal judgment debt of GH¢94 million owed to Tobinco Pharmaceuticals Ltd.
The debt stems from the unlawful destruction of unexpired drugs belonging to Tobinco Pharmaceuticals in 2013, during the tenure of former FDA CEO, Dr. Stephn Kwabena Opuni. However, it was not until 2019, six years later, that Tobinco’s CEO, Samuel Amo Tobbin, took the matter to court, under the current administration of Mimi Delese Darko.
The Herald’s findings suggest that the FDA is on the verge of paying a dubious judgment debt, despite having sufficient evidence and documentation to contest it. Notably, documents authored by the current CEO, Mimi Delese Darko, could have been used to challenge the court’s decision.
Sources close to the investigation reveal that the FDA seems reluctant to fight the judgment debt, sparking concerns of collusion between the regulatory body and Tobinco Pharmaceuticals. The delay in seeking redress and the failure to utilize available evidence have raised eyebrows, prompting calls for a thorough probe into the matter.
The Herald’s investigation is ongoing, and more revelations are expected in the coming days. As the saga unfolds, one thing is clear: the FDA’s handling of the situation has raised serious questions about its integrity and commitment to upholding justice.